Equities analysts expect Heska Corp (NASDAQ:HSKA) to report $0.75 earnings per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Heska’s earnings. The highest EPS estimate is $0.78 and the lowest is $0.71. Heska reported earnings of $0.63 per share during the same quarter last year, which suggests a positive year-over-year growth rate of 19%. The firm is expected to issue its next earnings results on Wednesday, February 27th.

On average, analysts expect that Heska will report full-year earnings of $1.74 per share for the current year, with EPS estimates ranging from $1.71 to $1.77. For the next fiscal year, analysts anticipate that the company will report earnings of $1.98 per share, with EPS estimates ranging from $1.96 to $2.00. Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Heska.

Heska (NASDAQ:HSKA) last issued its quarterly earnings data on Tuesday, November 6th. The medical research company reported $0.46 earnings per share for the quarter, beating analysts’ consensus estimates of $0.35 by $0.11. Heska had a return on equity of 11.48% and a net margin of 1.01%. The company had revenue of $30.96 million for the quarter, compared to the consensus estimate of $31.14 million.

Several brokerages have recently commented on HSKA. BidaskClub lowered Heska from a “hold” rating to a “sell” rating in a research note on Tuesday, October 9th. Zacks Investment Research raised Heska from a “hold” rating to a “buy” rating and set a $101.00 price objective for the company in a research report on Thursday. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $106.20.

In other news, Director G Irwin Gordon sold 6,700 shares of the stock in a transaction that occurred on Wednesday, November 21st. The shares were sold at an average price of $98.04, for a total transaction of $656,868.00. Following the sale, the director now directly owns 34,268 shares of the company’s stock, valued at $3,359,634.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Jason A. Napolitano sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, December 3rd. The shares were sold at an average price of $104.17, for a total transaction of $312,510.00. The disclosure for this sale can be found here. Insiders sold 18,702 shares of company stock worth $1,897,809 over the last ninety days. 15.90% of the stock is currently owned by company insiders.

Several large investors have recently modified their holdings of HSKA. FMR LLC boosted its holdings in shares of Heska by 81.9% during the 2nd quarter. FMR LLC now owns 459,211 shares of the medical research company’s stock worth $47,662,000 after buying an additional 206,814 shares during the period. Redmile Group LLC boosted its stake in shares of Heska by 48.8% in the 2nd quarter. Redmile Group LLC now owns 354,776 shares of the medical research company’s stock valued at $36,822,000 after purchasing an additional 116,330 shares during the last quarter. BlackRock Inc. boosted its stake in Heska by 10.6% during the second quarter. BlackRock Inc. now owns 1,027,636 shares of the medical research company’s stock worth $106,657,000 after acquiring an additional 98,875 shares in the last quarter. Raymond James & Associates lifted its stake in shares of Heska by 53.7% in the second quarter. Raymond James & Associates now owns 106,237 shares of the medical research company’s stock valued at $11,026,000 after buying an additional 37,139 shares in the last quarter. Finally, Grandeur Peak Global Advisors LLC raised its holdings in shares of Heska by 29.9% in the third quarter. Grandeur Peak Global Advisors LLC now owns 99,300 shares of the medical research company’s stock valued at $11,252,000 after purchasing an additional 22,850 shares during the last quarter. Institutional investors and hedge funds own 89.82% of the company’s stock.

Heska stock opened at $91.90 on Wednesday. Heska has a 12 month low of $56.59 and a 12 month high of $114.50. The company has a market capitalization of $713.24 million, a PE ratio of 44.40 and a beta of 0.88.

Heska Company Profile

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.

Read More: Yield Curve

Get a free copy of the Zacks research report on Heska (HSKA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.